(Reuters) - Valeant Pharmaceuticals International Inc said on Monday it would raise the discounts to hospitals on its heart drugs Nitropress and Isuprel to as much as 40 percent off list prices after shareholder William Ackman pledged to revisit controversial price increases on the treatments.
Valeant has been criticized by doctors and is being investigated by the U.S. Senate after having raised the price of Isuprel by about 720 percent and Nitropress by 310 percent after it bought the drugs from Marathon Pharmaceuticals in 2015.
The Canadian drugmaker, which acknowledged aggressive pricing practices during a U.S. congressional probe late last month, earlier this month formed a committee to oversee drug pricing policies.
Valeant had previously pledged to give hospitals volume-based discounts of up to 30 percent off the price, but U.S. Senators said during last month’s hearing that it believed hospitals were not receiving the after-market discounts.
The company said on Monday all hospitals were eligible for a rebate of at least 10 percent, with rebates totaling 20 percent, 30 percent or 40 percent based on the volume purchased during a quarter, Valeant said.
Valeant did not cut the list prices of the drugs.
The top Democrat on the U.S. House of Representatives’ oversight panel said on Monday that he was meeting today with Valeant’s new Chief Executive Joseph Papa to discuss how the pricing changes will be made and broader pricing policy issues.
“This is a small step in the right direction, but it comes nowhere close to fully addressing this critical problem,” Representative Elijah Cummings said in a statement.
Last month, activist investor Bill Ackman, whose investment in Valeant has lost more than $1 billion in value, testified to the Senate that the company was going to look at price cuts after it formed a committee.
The Senate also investigated the price increases on two other Valeant drugs, Syprine and Cuprimine, which are used to treat a rare genetic disorder called Wilson’s Disease.
Valeant shares fell 45 cents, or 1.7 percent, to $25.45 in midday New York trading. They peaked last August at $263.70.
Reporting by Caroline Humer in New York and Ankur Banerjee in Bengaluru; Editing by Bernadette Baum and Alan Crosby